Mechanisms of Xiaozheng decoction for anti-bladder cancer effects via affecting the GSK3β/β-catenin signaling pathways: a network pharmacology-directed experimental investigation.
Apoptosis
Bladder cancer
GSK3β/β-catenin
Network pharmacology
Xiaozheng decoction
Journal
Chinese medicine
ISSN: 1749-8546
Titre abrégé: Chin Med
Pays: England
ID NLM: 101265109
Informations de publication
Date de publication:
22 Aug 2023
22 Aug 2023
Historique:
received:
07
05
2023
accepted:
12
08
2023
medline:
23
8
2023
pubmed:
23
8
2023
entrez:
23
8
2023
Statut:
epublish
Résumé
The combination of Xiaozheng decoction with postoperative intravesical instillation has been shown to improve the prognosis of bladder cancer patients and prevent recurrence. However, the mechanisms underlying the efficacy of this herbal formula remain largely unclear. This research aims to identify the important components of Xiaozheng decoction and explore their anti-bladder cancer effect and mechanism using network pharmacology-based experiments. The chemical ingredients of each herb in the Xiaozheng decoction were collected from the Traditional Chinese Medicine (TCM) database. Network pharmacology was employed to predict the target proteins and pathways of action. Disease databases were utilized to identify target genes associated with bladder cancer. A Protein-Protein Interaction (PPI) network was constructed to illustrate the interaction with intersected target proteins. Key targets were identified using Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) functional enrichment analysis. A compound-target-pathway network was established after molecular docking predictions. In vitro experiments with bladder cancer cell lines were conducted using core chemical components confirmed by ultra-performance liquid chromatography quadrupole time-of-flight mass spectrometry (UPLC-qTOF-MS) to verify the conclusions of network pharmacology. 45 active compounds were extracted, and their relationships with Traditional Chinese Medicines (TCMs) and protein targets were presented, comprising 7 herbs, 45 active compounds, and 557 protein targets. The intersection between potential TCM target genes and bladder cancer-related genes yielded 322 genes. GO and KEGG analyses indicated that these targets may be involved in numerous cancer-related pathways. Molecular docking results showed that candidate compounds except mandenol could form stable conformations with the receptor. In vitro experiments on three bladder cancer cell lines demonstrated that quercetin and two other impressive new compounds, bisdemethoxycurcumin (BDMC) and kumatakenin, significantly promoted cancer cell apoptosis through the B-cell lymphoma 2/Bcl-2-associated X (Bcl-2/BAX) pathway and inhibited proliferation and migration through the glycogen synthase kinase 3 beta (GSK3β)/β-catenin pathway. By employing network pharmacology and conducting in vitro experiments, the mechanism of Xiaozheng decoction's effect against bladder cancer was tentatively elucidated, and its main active ingredients and targets were identified, providing a scientific basis for future research.
Identifiants
pubmed: 37608369
doi: 10.1186/s13020-023-00818-5
pii: 10.1186/s13020-023-00818-5
pmc: PMC10464372
doi:
Types de publication
Journal Article
Langues
eng
Pagination
104Subventions
Organisme : National Natural Science Foundation of China
ID : 82072821
Organisme : National Natural Science Foundation of China
ID : 92059112
Organisme : Shanghai Songjiang Municipal Science and Technology Commission Natural Science Foundation
ID : 20SJKJGG250
Informations de copyright
© 2023. International Society for Chinese Medicine and BioMed Central Ltd.
Références
Evid Based Complement Alternat Med. 2021 Nov 09;2021:7178414
pubmed: 34795788
Am J Cancer Res. 2016 Jan 15;6(2):498-508
pubmed: 27186419
J Healthc Eng. 2022 Mar 24;2022:8177674
pubmed: 35368948
Nucleic Acids Res. 2015 Jan;43(Database issue):D789-98
pubmed: 25428349
Urol Oncol. 2019 Jun;37(6):353.e9-353.e15
pubmed: 30737158
Oncol Lett. 2015 Jan;9(1):270-274
pubmed: 25435973
Nucleic Acids Res. 2006 Jan 1;34(Database issue):D668-72
pubmed: 16381955
Cancer Res. 2019 Mar 15;79(6):1019-1031
pubmed: 30808672
Chem Pharm Bull (Tokyo). 1992 Jan;40(1):143-7
pubmed: 1576664
J Ethnopharmacol. 2022 Feb 10;284:114801
pubmed: 34748868
J Altern Complement Med. 2008 Oct;14(8):1049-55
pubmed: 18928393
Cell. 2015 May 21;161(5):967-970
pubmed: 26000477
Cancer. 2009 Jan 1;115(1):68-74
pubmed: 19072984
J Ethnopharmacol. 2006 Feb 20;103(3):501
pubmed: 16376038
Front Cell Dev Biol. 2020 Aug 11;8:704
pubmed: 32850824
Cancer Med. 2019 May;8(5):1958-1975
pubmed: 30945475
Mater Sci Eng C Mater Biol Appl. 2020 May;110:110662
pubmed: 32204090
Int J Mol Sci. 2019 Aug 05;20(15):
pubmed: 31387245
Curr Protoc Bioinformatics. 2016 Jun 20;54:1.30.1-1.30.33
pubmed: 27322403
Onco Targets Ther. 2020 Sep 28;13:9587-9597
pubmed: 33061441
Antioxidants (Basel). 2019 Aug 21;8(9):
pubmed: 31438633
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2014 Aug;34(8):922-5
pubmed: 25223173
Pharmaceutics. 2022 Nov 20;14(11):
pubmed: 36432718
Front Pharmacol. 2019 Feb 21;10:123
pubmed: 30846939
Food Chem. 2012 Jul 15;133(2):416-22
pubmed: 25683414
Front Pharmacol. 2018 Apr 04;9:234
pubmed: 29670523
Biomed Pharmacother. 2016 Oct;83:526-535
pubmed: 27447121
Oncol Rep. 2022 Dec;48(6):
pubmed: 36222295
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Biomed Res Int. 2022 Mar 29;2022:9304552
pubmed: 35402614
Front Oncol. 2021 Aug 26;11:731522
pubmed: 34513708
Clin Cancer Res. 2017 Nov 1;23(21):6592-6601
pubmed: 28808039
Sci Rep. 2019 Dec 27;9(1):19977
pubmed: 31882719
Oncol Rep. 2014 Dec;32(6):2710-8
pubmed: 25333742
J Med Chem. 2019 May 9;62(9):4233-4251
pubmed: 30543440
Heliyon. 2023 Mar 07;9(3):e14309
pubmed: 36938447
Biomed Pharmacother. 2007 Jul;61(6):299-305
pubmed: 17604943
Cancer Cell. 2020 Apr 13;37(4):543-550
pubmed: 32289276
Signal Transduct Target Ther. 2020 May 8;5(1):51
pubmed: 32382060
Br J Cancer. 2018 Jan;118(1):3-8
pubmed: 29235562
Micron. 2021 Dec;151:103152
pubmed: 34607251
Virchows Arch. 2019 Feb;474(2):209-217
pubmed: 30483954
Chin J Nat Med. 2022 Jan;20(1):43-53
pubmed: 35101249
Front Pharmacol. 2022 Jul 14;13:932039
pubmed: 35910372
Nucleic Acids Res. 2019 Jul 2;47(W1):W357-W364
pubmed: 31106366
Virchows Arch. 2016 Nov;469(5):547-552
pubmed: 27514658
Transl Oncol. 2018 Apr;11(2):467-476
pubmed: 29477637
J Cheminform. 2014 Apr 16;6:13
pubmed: 24735618
Nat Rev Cancer. 2015 Jan;15(1):25-41
pubmed: 25533674
J Agric Food Chem. 2017 Sep 13;65(36):7893-7899
pubmed: 28763204
JCI Insight. 2023 Mar 22;8(6):
pubmed: 36757813